1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Peptides Biosimilars Revenue
1.4 Market Analysis by Type
1.4.1 Global Peptides Biosimilars Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Glucagon
1.4.3 Calcitonin
1.5 Market by Application
1.5.1 Global Peptides Biosimilars Market Share by Application: 2021-2026
1.5.2 Oncology
1.5.3 Chronic Diseases
1.5.4 Autoimmune Diseases
1.5.5 Blood Disorders
1.5.6 Growth Hormone Deficiency
1.5.7 Infectious Diseases
1.5.8 Other Diseases
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Peptides Biosimilars Market
1.8.1 Global Peptides Biosimilars Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Peptides Biosimilars Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Peptides Biosimilars Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Peptides Biosimilars Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Peptides Biosimilars Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Peptides Biosimilars Sales Volume Market Share by Region (2015-2020)
3.2 Global Peptides Biosimilars Sales Revenue Market Share by Region (2015-2020)
3.3 North America Peptides Biosimilars Sales Volume
3.3.1 North America Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.3.2 North America Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Peptides Biosimilars Sales Volume
3.4.1 East Asia Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Peptides Biosimilars Sales Volume (2015-2020)
3.5.1 Europe Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Peptides Biosimilars Sales Volume (2015-2020)
3.6.1 South Asia Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Peptides Biosimilars Sales Volume (2015-2020)
3.7.1 Southeast Asia Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Peptides Biosimilars Sales Volume (2015-2020)
3.8.1 Middle East Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Peptides Biosimilars Sales Volume (2015-2020)
3.9.1 Africa Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Peptides Biosimilars Sales Volume (2015-2020)
3.10.1 Oceania Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Peptides Biosimilars Sales Volume (2015-2020)
3.11.1 South America Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.11.2 South America Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Peptides Biosimilars Sales Volume (2015-2020)
3.12.1 Rest of the World Peptides Biosimilars Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Peptides Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Peptides Biosimilars Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Peptides Biosimilars Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Peptides Biosimilars Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Peptides Biosimilars Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Peptides Biosimilars Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Peptides Biosimilars Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Peptides Biosimilars Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Peptides Biosimilars Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Peptides Biosimilars Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Peptides Biosimilars Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Peptides Biosimilars Sales Volume Market Share by Type (2015-2020)
14.2 Global Peptides Biosimilars Sales Revenue Market Share by Type (2015-2020)
14.3 Global Peptides Biosimilars Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Peptides Biosimilars Consumption Volume by Application (2015-2020)
15.2 Global Peptides Biosimilars Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Peptides Biosimilars Business
16.1 Sandoz
16.1.1 Sandoz Company Profile
16.1.2 Sandoz Peptides Biosimilars Product Specification
16.1.3 Sandoz Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Mylan
16.2.1 Mylan Company Profile
16.2.2 Mylan Peptides Biosimilars Product Specification
16.2.3 Mylan Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Celltrion
16.3.1 Celltrion Company Profile
16.3.2 Celltrion Peptides Biosimilars Product Specification
16.3.3 Celltrion Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Pfizer
16.4.1 Pfizer Company Profile
16.4.2 Pfizer Peptides Biosimilars Product Specification
16.4.3 Pfizer Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Samsung Biologics
16.5.1 Samsung Biologics Company Profile
16.5.2 Samsung Biologics Peptides Biosimilars Product Specification
16.5.3 Samsung Biologics Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Teva Pahrmaceutical
16.6.1 Teva Pahrmaceutical Company Profile
16.6.2 Teva Pahrmaceutical Peptides Biosimilars Product Specification
16.6.3 Teva Pahrmaceutical Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Stada Arzneimittel AG
16.7.1 Stada Arzneimittel AG Company Profile
16.7.2 Stada Arzneimittel AG Peptides Biosimilars Product Specification
16.7.3 Stada Arzneimittel AG Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Amgen
16.8.1 Amgen Company Profile
16.8.2 Amgen Peptides Biosimilars Product Specification
16.8.3 Amgen Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Biocon
16.9.1 Biocon Company Profile
16.9.2 Biocon Peptides Biosimilars Product Specification
16.9.3 Biocon Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Dr. Reddy's Laboratories
16.10.1 Dr. Reddy's Laboratories Company Profile
16.10.2 Dr. Reddy's Laboratories Peptides Biosimilars Product Specification
16.10.3 Dr. Reddy's Laboratories Peptides Biosimilars Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Peptides Biosimilars Manufacturing Cost Analysis
17.1 Peptides Biosimilars Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Peptides Biosimilars
17.4 Peptides Biosimilars Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Peptides Biosimilars Distributors List
18.3 Peptides Biosimilars Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Peptides Biosimilars (2021-2026)
20.2 Global Forecasted Revenue of Peptides Biosimilars (2021-2026)
20.3 Global Forecasted Price of Peptides Biosimilars (2015-2026)
20.4 Global Forecasted Production of Peptides Biosimilars by Region (2021-2026)
20.4.1 North America Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.3 Europe Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.7 Africa Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.9 South America Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Peptides Biosimilars Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Peptides Biosimilars by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Peptides Biosimilars by Country
21.2 East Asia Market Forecasted Consumption of Peptides Biosimilars by Country
21.3 Europe Market Forecasted Consumption of Peptides Biosimilars by Countriy
21.4 South Asia Forecasted Consumption of Peptides Biosimilars by Country
21.5 Southeast Asia Forecasted Consumption of Peptides Biosimilars by Country
21.6 Middle East Forecasted Consumption of Peptides Biosimilars by Country
21.7 Africa Forecasted Consumption of Peptides Biosimilars by Country
21.8 Oceania Forecasted Consumption of Peptides Biosimilars by Country
21.9 South America Forecasted Consumption of Peptides Biosimilars by Country
21.10 Rest of the world Forecasted Consumption of Peptides Biosimilars by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer